Browse the corpus

Adalimumab is a fully human, recombinant monoclonal antibody with high affinity and was the third tumor necrosis factor-alpha (TNF-α) inhibitor. Adalimumab is used to treat various autoimmune conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn disease, and ulcerative colitis. The original adalimumab molecule received its initial approval from the U.S. Food and Drug Administration (FDA) for treating rheumatoid arthritis. This activity comprehensively reviews the indications, mechanism of action, administration, potential adverse effects, and contraindications of adalimumab, providing the interprofessional healthcare team with the necessary information to effectively utilize the drug and treat certain autoimmune conditions. This topic also emphasizes the warnings, precautions, and potential drug-drug interactions associated with adalimumab when administered to patients with autoimmune disorders. Objectives: Identify appropriate indications for adalimumab therapy based on the patient's medical history, clinical presentation, and relevant diagnostic findings. Implement a standardized dosing and monitoring protocol for patients initiating adalimumab therapy, ensuring adherence to recommended treatment regimens. Assess patient response to adalimumab treatment, including evaluating changes in disease activity, symptoms, and adverse events. Collaborate with multidisciplinary healthcare teams, including rheumatologists, gastroenterologists, nurses, and pharmacists, to provide comprehensive patient care, improve patient outcomes, and address complex patient needs. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose Adalimumab has an unknown toxicity profile, as there have been no long-term studies conducted on humans or animals. Furthermore, the drug has not exhibited mutagenic effects in either in vitro or in vivo studies.[41] The FDA classifies adalimumab as a pregnancy category B drug. However, published evidence does not conclusively demonstrate adverse pregnancy outcomes or specific patterns of defects in infants exposed to adalimumab during pregnancy.[42] Reported cases of hepatotoxicity associated with adalimumab have typically presented as mild and self-limiting. Management of Overdose Patients who develop an autoimmune hepatitis-like syndrome while undergoing adalimumab therapy may not experience a swift recovery upon discontinuing adalimumab and could necessitate corticosteroid treatment. In such instances, the corticosteroid dosage should be minimized to manage the condition effectively. In addition, efforts should be made to withdraw or reduce immunosuppression to levels used before adalimumab administration.[1]

The successful administration of TNF-α antagonists, including adalimumab, necessitates the involvement of an interprofessional healthcare team equipped with comprehensive knowledge and practical experience in managing these medications. Several important considerations for interprofessional healthcare teams are listed below. The healthcare provider must ensure that the agent is genuinely indicated for the specific clinical context. The healthcare provider should conduct thorough baseline fitness investigations, including CBC, liver, and renal function tests. In addition, it is essential to ensure that the patient is neither in congestive cardiac failure nor at risk of it. The healthcare team must prioritize ruling out any underlying infections, as TNF-α antagonist therapy may exacerbate their symptoms. In regions where tuberculosis is prevalent, the likelihood of a latent tuberculosis focus reactivating is considerable. Therefore, conducting a chest x-ray and Mantoux test is paramount before commencing treatment. The healthcare team should maintain vigilant monitoring of the patient throughout the course of treatment to promptly detect and track the development of any adverse effects. When clinicians prescribe adalimumab or similar medications, they should collaborate with a clinical pharmacist to evaluate potential interactions and confirm the patient's suitability for the treatment. Both nurses and pharmacists are well-equipped to guide dosing and administration, especially when the patient is responsible for self-administering the pen. In a study involving ulcerative colitis patients with poor medication adherence, which included adalimumab, pharmacist intervention significantly reduced nonadherence rates (from 60.6% to 30.3%; P = .013). Furthermore, this intervention independently reduced the risk of disease flare-ups (adjusted odds ratio, 0.370; 95% CI, 0.145 to 0.945; P = .03). This study underscores the essential role of pharmacists within an interprofessional team in enhancing outcomes for ulcerative colitis patients with low adherence.[43]

In a study involving ulcerative colitis patients with poor medication adherence, which included adalimumab, pharmacist intervention significantly reduced nonadherence rates (from 60.6% to 30.3%; P = .013). Furthermore, this intervention independently reduced the risk of disease flare-ups (adjusted odds ratio, 0.370; 95% CI, 0.145 to 0.945; P = .03). This study underscores the essential role of pharmacists within an interprofessional team in enhancing outcomes for ulcerative colitis patients with low adherence.[43] Patients with severe rheumatoid arthritis should seek consultation with rheumatologists. For individuals with hidradenitis suppurativa, dermatology consultation may be necessary. In addition, it is crucial for all members of the interprofessional team, including clinicians (MD, DO, NP, and PA), specialists, pharmacists, and nurses, to maintain open and consistent communication regarding any changes in the patient's condition, whether favorable or unfavorable, throughout the course of therapy. This high level of care coordination ultimately results in improved patient outcomes while minimizing the risk of adverse effects.